^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cetuximab biosimilar

    Associations

    News

    Trials
    Company:
    CinnaGen
    Drug class:
    EGFR inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=234, Recruiting, Cinnagen | Unknown status --> Recruiting | Trial completion date: Feb 2020 --> Feb 2026 | Trial primary completion date: Nov 2019 --> Nov 2025
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • RAS (Rat Sarcoma Virus)
    |
    EGFR expression • RAS wild-type
    |
    Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium • cetuximab biosimilar